SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.…
SAB Biotherapeutics (SABS) Q3 2026 Earnings Call Transcript
SAB Biotherapeutics (NASDAQ: SABS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 86 employees.
The shares were at 2.810 USD on 20 November 2026, down 9.4% over 52 weeks. Its 52-week range is 2.441 USD to 5.150 USD: the price is 45.4% below the high and 15.1% above the low.
Its market capitalisation is 253.15M USD.
SAB Biotherapeutics reports return on equity of 8.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 99.13M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 25 February 2027.